ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,101.16
1.04%
US Tech 100
17,239.87
1.54%
Dow Jones
38,232.58
0.39%
Brent Oil
88.315
0.19%
Bitcoin
63,509.17
-1.51%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kiniksa Pharmaceuticals Ltd (KNSA) Quote

Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd (KNSA)

NASDAQ
17.93
0.32
( 1.82% )
Updated: 11:39:37
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
17.93
Bid
17.83
Ask
17.86
Volume
53,094
17.45 Day's Range 18.0513
10.645 52 Week Range 22.10
Market Cap
1.266B
Previous Close
17.61
Open
17.84
Last Trade
15
@
17.845
Last Trade Time
11:39:56
Financial Volume
$ 951,978
VWAP
17.9301
Average Volume (3m)
377,584
Shares Outstanding
70,615,022
Dividend Yield
-
PE Ratio
89.92
Earnings Per Share (EPS)
0.2
Revenue
270.26M
Net Profit
14.08M

About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kiniksa.com
Headquarters
Hamilton, Bmu
Founded
1970
Kiniksa Pharmaceuticals Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $17.61. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 10.645 to $ 22.10.

Kiniksa Pharmaceuticals currently has 70,615,022 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $1.27 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of 89.92.

KNSA Latest News

More News

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million ––...

April 23 2024
GlobeNewswire Inc.

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024...

April 16 2024
GlobeNewswire Inc.

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 –– Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity –– Abiprubart...

April 02 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

March 01 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 29 2024
Edgar (US Regulatory)

Form 8-K - Current report

February 28 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.066.283343212816.8718.6116.5645399717.47987656CS
4-1.71-8.706720977619.6419.7316.5637431717.69964162CS
12-0.17-0.93922651933718.122.116.5637758419.39866541CS
262.6817.573770491815.2522.114.1243158018.19322217CS
526.962.556663644611.0322.110.64543444517.18781296CS
1561.529.2626447288216.4122.17.3639256414.23276881CS
2601.9912.484316185715.94335.0135442415.31095412CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.33
(83.50%)
55.68M
NIVFNewGenIvf Group Ltd
$ 2.0799
(59.99%)
47.8M
FCUVFocus Universal Inc
$ 0.4243
(49.88%)
15.64M
IFBDInfobird Company Ltd
$ 5.1999
(40.92%)
751.81k
PEGYPineapple Energy Inc
$ 0.0727
(40.08%)
253.76M
ISUNiSun Inc
$ 0.1589
(-95.39%)
7.48M
NWGLNature Wood Group Ltd
$ 5.25
(-68.84%)
488.12k
ICLKiClick Interactive Asia Group Ltd
$ 1.405
(-44.47%)
562.35k
NUWENewellis Inc
$ 0.1726
(-40.28%)
14.12M
SGBXSafe and Green Holdings Corporation
$ 0.1561
(-28.72%)
5.21M
PEGYPineapple Energy Inc
$ 0.0727
(40.08%)
253.76M
SQQQProShares UltraPro Short QQQ
$ 11.4676
(-4.44%)
77.75M
INTCIntel Corporation
$ 31.6145
(-9.96%)
61.63M
BDRXBiodexa Pharmaceuticals PLC
$ 1.33
(83.50%)
55.68M
NIVFNewGenIvf Group Ltd
$ 2.0799
(59.99%)
47.8M

KNSA Discussion

View Posts
DonDonDonDon DonDonDonDon 3 years ago
No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
👍️0
DonDonDonDon DonDonDonDon 3 years ago
It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

https://www.bbc.com/news/health-56352128

Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
👍️0
Femto99 Femto99 3 years ago
PT= $30-40 (by or around March 31st)
https://msmoneymoves.com/2021/02/17/knsa-report/
👍️0
Femto99 Femto99 3 years ago
PDUFA Mar21
👍️0

Your Recent History

NASDAQ
KNSA
Kiniksa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved